News
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024.
Fourth Quarter 2024 Financial Highlights:
-
Revenue grew 8%
Humana and Monogram Health Announce Expansion of Comprehensive Kidney Care Program
Humana and Monogram Health are pleased to announce a significant expansion, extending member access to in-home treatment for kidney disease and its underlying causes. Eligible Humana Medicare
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI
QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up results from the Phase 3 EV-302 clinical trial (also
Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting
Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance(5) provided on December 17, 2024.
The fourth-quarter 2024
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with
Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. Management will hold
Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year and 29.0% CORE EBITDA Margin
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6
Agilent to Announce First-Quarter Fiscal Year 2025 Financial Results on Feb. 26
Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host
Agilent Automated Workflows at SLAS2025: Connecting with Confidence
Agilent Technologies Inc. (NYSE: A) announced today that it will feature new automated laboratory workflow solutions at the SLAS2025 International Conference & Exhibition being held January 25-29
Leaps by Bayer Announces One of the Largest Global Surveys of Society’s Attitudes Toward Breakthrough Technologies
As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the
QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and
Agilent Presents Solutions Innovation Research Awards to Aarhus University, University of Graz, and Imperial College London Scientists
Agilent Technologies Inc. (NYSE: A) today announced Solutions Innovation Research Awards (SIRA) have been presented to Professor Anders Bentien of Aarhus University, Professor Walter Gössler of
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds
Humana Earns Equality 100 Award in Human Rights Campaign Foundation’s 2025 Corporate Equality Index
Leading health insurer and health care services company Humana Inc. (NYSE: HUM), has earned a score of 100 on the Human Rights Campaign Foundation (HRCF) Corporate Equality Index (CEI) for the 11th